false
0000827871
0000827871
2024-03-08
2024-03-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13
or 15(d)
of the Securities Exchange
Act of 1934
Date of Report (Date
of earliest event reported): March 8, 2024
Eagle
Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in its
Charter)
Delaware |
001-36306 |
20-8179278 |
(State
or Other Jurisdiction
of Incorporation) |
(Commission
File Number) |
(IRS Employer
Identification No.) |
50
Tice Boulevard, Suite 315
Woodcliff Lake, NJ |
|
07677 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone
number, including area code: (201) 326-5300
Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section
12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.001 per share |
|
EGRX |
|
The
Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ¨
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On March 8, 2024, Brian Cahill
resigned from his position as Chief Financial Officer of Eagle Pharmaceuticals, Inc. (the “Company”), effective
immediately. The Board of Directors of the Company (the “Board”) has instituted a search for Mr. Cahill’s
successor as Chief Financial Officer.
In connection with Mr. Cahill’s
separation, Steven Ratoff, a member of the Board and Chair of the Audit Committee of the Board (the “Audit Committee”),
was appointed Interim Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of the Company, effective immediately, to serve
until such time as a new Chief Financial Officer commences employment or such other date determined by the Board or upon his earlier
resignation. Mr. Ratoff remains a member of the Board.
In connection with Mr. Ratoff’s appointment
as Interim Chief Financial Officer, Mr. Ratoff stepped down from each of the Audit Committee and Compensation Committee of the Board
(the “Compensation Committee”). Following Mr. Ratoff’s stepping down from these committees, the members of the
Audit Committee of the Board are Robert Glenning (Chair), Jennifer Simpson and Richard Edlin, the members of the Compensation Committee
are Dr. Simpson (Chair), Mr. Edlin and Luciana Borio, and the members of the Nominating and Corporate Governance Committee
are Mr. Edlin (Chair), Mr. Glenning, Dr. Simpson and Dr. Borio. In addition, the Board appointed Dr. Simpson
to serve as the Lead Independent Director of the Board.
Mr. Ratoff has served as a member of the
Board since March 2007. Mr. Ratoff has served as the Chief Executive Officer of CM Systems LLC, a cloud-based software company,
since July 2018. Mr. Ratoff’s prior experience includes serving as a Venture Partner for ProQuest Investments from 2005
to 2013, as Chief Executive Officer of Novadel Pharma, Inc., a specialty pharmaceutical company, from 2007 to 2012, and as Chief
Executive Officer of CIMA Labs, Inc., a specialty pharmaceutical company acquired by Cephalon in 2004. In addition, Mr. Ratoff
served as Chief Financial Officer of the Brown-Forman Company from 1995 to 2001. Mr. Ratoff holds a B.S. in business administration
from Boston University and an M.B.A. with Distinction from the University of Michigan.
Cahill Separation Agreement
In connection with Mr. Cahill’s resignation,
the Board determined that it is in the best interests of the Company and its stockholders to provide certain compensation and benefits
to Mr. Cahill in exchange for his continued assistance, consulting services and other obligations, as set forth in a Separation
Agreement between Mr. Cahill and the Company, dated as of March 8, 2024 (the “Separation Agreement”). Under the
Separation Agreement, Mr. Cahill has agreed to serve as a non-employee consultant to the Company for a six month period after his
separation (the “Consulting Period”). During the first three months of the Consulting Period, Mr. Cahill will receive
a monthly cash retainer of $35,000.00 for up to a maximum of 40 hours per week. During the remaining three months of the Consulting Period,
Mr. Cahill will receive a monthly cash retainer of $17,500.00 for up to a maximum of 20 hours per week. During the Consulting Period,
Mr. Cahill will assist with matters relating to the transition of his work and responsibilities on behalf of the Company. Both parties
have the right to terminate the Consulting Period upon 30 days written notice to the other party and the Company has the right to terminate
the Consulting Period upon the invocation of the clawback provisions described below.
Under
the Separation Agreement, subject to Mr. Cahill’s release of claims and continued compliance with his ongoing obligations,
the Company has agreed to provide Mr. Cahill with: (1) cash severance in the amount of (x) 12 months of Mr. Cahill’s
annual base salary plus (y) Mr. Cahill’s annual target cash bonus for 2024, paid in substantially equal installments
over 12 months (the “Cash Severance Payment”); (2) continued COBRA premium payments for up to 12 months; and (3) with
respect to Mr. Cahill’s stock options and restricted stock unit awards that are subject solely to a time-based vesting schedule
(the “Time Based Awards”), those awards shall continue to remain outstanding and exercisable, as applicable, through the
12-month anniversary of his separation (the “One Year Separation Anniversary”), but shall not vest on their regular vest
dates during such time. Upon the One Year Separation Anniversary, Mr. Cahill shall receive vesting acceleration of the Time Based
Awards that were scheduled to vest pursuant to the vesting schedule of such Time Based Awards over the 12 month period immediately following
Mr. Cahill’s separation date and Mr. Cahill shall have six months following the One Year Separation Anniversary to exercise
his then-outstanding and vested stock options, subject to earlier termination of such awards pursuant to their terms and the Equity Plan.
Mr. Cahill will forfeit all rights to the performance-vesting awards that he holds as of the Separation Date.
The Separation Agreement includes Mr. Cahill’s
release of claims in favor of the Company, subject to customary exceptions, and mutual covenants not to disparage. Additionally, the
Separation Agreement contains clawback provisions providing for, in addition to any required clawback under applicable law or listing
requirements and the Company’s Incentive Compensation Recoupment Policy, the Board’s ability to recoup or cancel payment
of severance and/or equity compensation upon certain designated events, including a finding that Mr. Cahill engaged in conduct constituting
“cause” as defined in the Company’s 2014 Equity Incentive Plan or materially breached his continuing obligations to
the Company or upon certain findings by a court or government agency.
In addition, pursuant to the Separation Agreement,
Mr. Cahill has agreed to cooperate with the Company in connection with certain matters and to refrain from taking certain actions
with respect to the Company and its management and stockholders, and his shares of Company common stock.
The foregoing description of the Separation Agreement
does not purport to be complete and is qualified in its entirety by reference to the full text of the Separation Agreement, which
is filed as Exhibit 10.1 to this Current Report on Form 8-K.
Ratoff Offer Letter
In connection with the
appointment of Mr. Ratoff as the Interim Chief Financial Officer of the Company, on March 8, 2024, the Company and Mr. Ratoff
entered into an offer letter (the “Offer Letter”) providing for monthly cash compensation of $154,000 for the first three
months of the Term (as defined below) and $77,000 for any remaining months during the Term. During Mr. Ratoff’s Term as Interim
Chief Financial Officer of the Company, Mr. Ratoff will not be eligible for participation in the Company’s executive bonus
program or the Company’s severance plans. During the Term, Mr. Ratoff will not be eligible for compensation (either in the
form of cash or equity) under the Company’s non-employee director compensation program, although he remains on the Board, and equity
previously granted to him in his capacity as a non-employee director continues to vest. Mr. Ratoff’s employment is on an at-will
basis, with an expected term of less than 12 months (the “Term”), which may be terminated sooner or may be extended by mutual
agreement.
The
Company and Mr. Ratoff previously entered into the Company’s standard director and officer indemnification agreement, in the
form previously adopted and disclosed by the Company and filed as Exhibit 10.1 to the Company’s Registration
Statement on Form S-1 filed with the SEC on December 20, 2013, in connection with his prior service on the Board.
The description of the
Offer Letter is only a summary, does not purport to be complete and is qualified in its entirety by the full text of the Offer Letter,
a copy of which is attached hereto as Exhibit 10.2 and incorporated herein by reference.
Termination of Tarriff
Consulting
In addition to the
foregoing, the Company determined that it will not need the consulting services of Scott Tarriff, the Company's former President and
Chief Executive Officer, going forward and terminated Mr. Tarriff’s consulting services, effective February 29,
2024, pursuant to the terms of Mr. Tarriff’s separation agreement previously disclosed in the Company’s Current
Report on Form 8-K filed with the SEC on November 29, 2023.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
* | Certain
schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company undertakes
to furnish supplemental copies of any of the omitted schedules to the SEC upon request. |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Date: March 8, 2024 |
|
|
EAGLE PHARMACEUTICALS, INC. |
|
|
|
By: |
/s/ Michael Graves |
|
|
Michael Graves |
|
|
Interim Executive Chairman of the Board and |
|
|
Interim Principal Executive Officer |
Exhibit 10.1
March 8, 2024
Brian Cahill
VIA EMAIL
Dear Brian:
This letter sets forth the substance of the separation
agreement (the “Agreement”) that Eagle Pharmaceuticals, Inc. (the “Company”)
is offering to you to aid in your employment transition.
1. Resignation
and Separation Date. You have tendered and the Company hereby accepts your resignation from your
employment with the Company. Your resignation date with the Company will be today (the “Separation Date”). As
of the Separation Date, you will cease to serve as Chief Financial Officer, and as an officer of the Company and any subsidiary or affiliate
of the Company, and any role or position in which you are acting as a representative or agent of the Company (except as set forth herein
with respect to the Consulting Period, as defined below).
2. Accrued
Salary. In the next regularly scheduled Company payroll cycle after the Separation Date, the
Company will pay you all accrued salary and all accrued and unused vacation/PTO, if applicable, earned through the Separation Date. You
are entitled to this payment by law and it will be subject to all applicable standard payroll deductions and withholdings.
3. Severance.
In consideration of your timely execution of this Agreement and compliance with your continuing obligations to the Company hereunder and
under any agreement, plan or policy, the Company will provide you with the following severance benefits (the “Severance Benefits”):
| (a) | The Company will make severance payments to you in an amount equal to twelve (12) months of
your current base salary in the total amount of $423,340, plus 100% of your 2024 Target Bonus in the total amount of $254,004 less applicable
deductions and withholdings (together, the “Cash Severance Payment”). The Cash Severance Payment shall be made
in substantially equal installments over a twelve (12) month period (the “Severance Period”), paid on the Company’s
ordinary payroll dates, beginning with the first such date which occurs at least eight (8) business days following the Effective
Date (as defined herein). |
Brian Cahill
March 8, 2024
Page 2
| (b) | If you timely elect continued coverage under COBRA in the Company’s group health plans, then, as
an additional Severance Benefit, the Company will pay the full COBRA premium to continue your coverage (including coverage for eligible
dependents, if applicable) in effect for yourself (and your eligible dependents, if applicable) until the earliest of: (A) twelve
(12) months following the Separation Date; (B) the expiration of your eligibility for the continuation coverage under COBRA;
or (C) the date when you become eligible for substantially equivalent health insurance coverage in connection with new employment
or self-employment (such period from the Separation Date through the earliest of (A) through (C), the “COBRA Payment
Period”). Notwithstanding the foregoing, if at any time the Company determines, in its sole discretion, that the payment
of the COBRA premiums would result in a violation of the nondiscrimination rules of Section 105(h)(2) of the Code or any
statute or regulation of similar effect (including but not limited to the 2010 Patient Protection and Affordable Care Act, as amended
by the 2010 Health Care and Education Reconciliation Act), then provided you remain eligible for reimbursement in accordance with this
Section 3(b), in lieu of providing the COBRA premiums, the Company will instead pay you on the last day of each remaining month of
the COBRA Payment Period, a fully taxable cash payment equal to the COBRA premiums for that month, subject to applicable tax withholdings
for the remainder of the COBRA Payment Period. You may, but are not obligated to, use the Company’s COBRA reimbursement payment
toward medical expenses. If you become eligible for coverage under another employer’s group health plan through self-employment
or otherwise cease to be eligible for COBRA during the period provided in this clause, you must immediately notify the Company of such
event, and all payments and obligations under this clause will cease. |
4. Equity
Awards. You and the Company acknowledge that you have been granted certain equity awards (the
“Awards”) during your employment with the Company, pursuant to the Company’s 2014 Equity Incentive Plan
(the “Equity Plan”), and Exhibit A sets forth all such Awards that are outstanding as of the Separation
Date. As detailed in Exhibit A, certain of the Awards are subject to a time-based vesting schedule (the “Time
Based Awards”) and certain of the Awards are eligible to vest based upon the achievement of certain performance milestones
(the “Performance Awards”). Except as set forth in this Section 4, vesting will cease as of the Separation
Date.
Performance
Awards. You will forfeit all rights to all outstanding Performance Awards that you hold as of the Separation Date.
Provided you execute this Agreement
and comply with your continuing obligations to the Company under this Agreement, including your obligations to provide continued cooperation
under Section 13, then your Time Based Awards, including both the stock options and restricted stock units (but not your Performance
Awards) shall be treated as follows: (1) such awards shall continue to remain outstanding (as if your employment continued) and exercisable,
as applicable, following your Separation Date through the 12 month anniversary of your Separation Date (the “One Year Separation
Anniversary”), but shall not vest on their regular vest dates during such time; (2) upon the One Year Separation Anniversary,
you shall receive vesting acceleration of the Time Based Awards that were scheduled to vest pursuant to the vesting schedule of such Time
Based Awards over the twelve (12) month period immediately following your Separation Date and (3) you shall have six (6) months
following the One Year Separation Anniversary to exercise your then-outstanding and vested stock options, subject to earlier termination
of such awards pursuant to their terms and the Equity Plan. Any Time Based Awards that are restricted stock units that are not scheduled
to vest during the twelve (12) month period following your Separation Date shall be forfeited as of your Separation Date. For avoidance
of doubt, upon a Clawback Event (as described in Section 20), all vesting will immediately cease and you will immediately forfeit
all of your then-outstanding Equity Awards. Except as provided herein, your Time Based Awards shall remain subject to the terms under
which they were granted.
Brian Cahill
March 8, 2024
Page 3
5. Health
Insurance. Unless you follow the procedures set forth in this Section, your participation in
the Company’s group health insurance plan will end on the last day of the month in which the Separation Date occurs. To the extent
provided by the federal COBRA law or, if applicable, state insurance laws, and by the Company’s current group health insurance policies,
you will be eligible to continue your group health insurance benefits following the Separation Date. Later, you may be able to convert
to an individual policy through the provider of the Company’s health insurance, if you wish. You will be provided with a separate
notice describing your rights and obligations under COBRA and a form for electing COBRA coverage.
6. Other
Compensation or Benefits. You acknowledge that, except as expressly provided in this Agreement,
you have not earned and will not receive from the Company any additional compensation (including base salary, bonus, incentive compensation,
or equity), severance, or benefits after the Separation Date, with the exception of any vested right you may have under the express terms
of a written ERISA-qualified benefit plan (e.g., 401(k) account) or any vested stock options.
7. Expense
Reimbursements. You agree that, within five (5) calendar days after the Separation Date,
you will submit your final documented expense reimbursement statement reflecting all business expenses you incurred through the Separation
Date, if any, for which you seek reimbursement. The Company will reimburse you for these expenses pursuant to its regular business practice
and policies.
8. Release
of Claims.
(a) Scope
of Release. In exchange for the consideration provided to you under this Agreement to which you
would not otherwise be entitled, you hereby generally and completely release the Company, and its affiliated, related, parent and subsidiary
entities, and its and their current and former directors, officers, employees, shareholders, partners, agents, investors, administrators,
attorneys, benefit plans, plan administrators, professional employer organization or co-employer, trustees, divisions, predecessors, successors,
insurers, affiliates, and assigns (collectively, the “Releasees”) from any and all claims, liabilities, demands,
causes of action, and obligations, both known and unknown, arising from or in any way related to events, acts, conduct, or omissions occurring
at any time prior to and including the date you sign this Agreement. This general release includes, but is not limited to: (a) all
claims arising from or in any way related to your employment or relationship with the Releasees or the termination of that employment
or relationship; (b) all claims related to your compensation or benefits from the Releasees, including salary, bonuses, commissions,
vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership, equity, or profits
interests in the Company; (c) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good
faith and fair dealing; (d) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation
of public policy; and (e) all federal, state, and local statutory claims, including claims for discrimination, harassment, retaliation,
attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the Age Discrimination in Employment
Act, as amended (the “ADEA”), the New Jersey Law Against Discrimination, the New Jersey Equal Pay Act, the New
Jersey Conscientious Employee Protection Act, the New Jersey Civil Rights Act, the New Jersey Family Leave Act, the New Jersey State Wage
and Hour Law, and the New Jersey Wage Withholding Protection Law, all as amended.
Brian Cahill
March 8, 2024
Page 4
(b) Exceptions.
Notwithstanding the foregoing, you are not releasing the Releasees hereby from: (i) any obligation to indemnify you pursuant to the
Articles and Bylaws of the Company or any of the other Releasees, any valid fully executed indemnification agreement with the Company
or any of the other Releasees, applicable law, or applicable directors and officers liability insurance; (ii) any claims that cannot
be waived by law; or (iii) any claims for breach of this Agreement.
(c) Protected
Rights. You understand that nothing in this Agreement limits your ability to file a charge or
complaint with the Equal Employment Opportunity Commission, the Department of Labor, the National Labor Relations Board, the Occupational
Safety and Health Administration, the Securities and Exchange Commission, or any other federal, state, or local governmental agency or
commission (“Government Agencies”). You further understand this Agreement does not limit your ability to communicate
with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency,
including providing documents or other information, without notice to the Company. While this Agreement does not limit your right to receive
an award for information provided to the Securities and Exchange Commission, you understand and agree that, to the maximum extent permitted
by law, you are otherwise waiving any and all rights you may have to individual relief based on any claims that you have released and
any rights you have waived by signing this Agreement. Nothing in this Agreement waives any rights you may have under Section 7 of
the National Labor Relations Act (subject to the release of claims set forth herein).
Brian Cahill
March 8, 2024
Page 5
9. Return
of Company Property. You agree that within ten (10) days of the termination of the Consulting
Period (as defined below), you will return to the Company all Company documents (and all copies thereof) and other Company property in
your possession or control, including, but not limited to, Company files, emails, notes, drawings, records, plans, forecasts, reports,
studies, analyses, proposals, agreements, drafts, financial and operational information, research and development information, sales and
marketing information, customer lists, prospect information, pipeline reports, sales reports, personnel information, specifications, code,
software, databases, computer-recorded information, tangible property and equipment (including, but not limited to, computing and electronic
devices, mobile telephones, servers), credit cards, entry cards, identification badges and keys; and any materials of any kind which contain
or embody any proprietary or confidential information of the Company (and all reproductions or embodiments thereof in whole or in part).
You agree that you will make a diligent search to locate any such documents, property and information as soon as possible and no later
than five (5) days after the Separation Date. If you have used any personally owned computer or other electronic device, server,
or e-mail system to receive, store, review, prepare or transmit any Company confidential or proprietary data, materials or information,
within five (5) days after the Separation Date, you shall provide the Company with a computer-useable copy of such information and
then, following consultation with the Company, permanently delete and expunge such Company confidential or proprietary information from
those systems; and you agree to provide the Company access to your system as requested to verify that the necessary copying and/or deletion
is completed.
10. Proprietary
Information Obligations. You acknowledge and reaffirm any continuing obligations under any confidentiality,
non-disclosure and developments agreement, non-competition, non-solicitation, or similar type agreement between you and the Company, including
your Intellectual Property Assignment, Non-Disclosure, And Restrictive Covenant Agreement (the “Restricted Covenant Agreement”),
attached as Exhibit B.
11. Mutual
Non-disparagement. Except to the extent permitted by the Protected Rights section above, you
agree to refrain from any disparaging statements about the Company or any of the other Releasees, including, without limitation, the business,
products, intellectual property, financial standing, future, or employment/compensation/benefit practices of the Company or any of the
other Releasees; provided that you may respond accurately and fully to any request for information if required by legal process or in
connection with a governmental investigation. The Company agrees not to disparage you in any manner likely to be harmful to you or your
business, business reputation or personal reputation; provided that the Company may respond accurately and fully to any question, inquiry
or request for information when required by legal process, in connection with any of its communications with Government Agencies or other
regulatory bodies and/or when required to conduct its business and the Company may provide such disclosures as are required by the SEC
or other regulatory bodies, applicable listing rules or other applicable laws or regulations. The Company’s obligations under
this Section are limited to Company representatives with knowledge of this provision. In addition, nothing in this provision or this
Agreement prohibits or restrains you from making disclosures protected under the whistleblower provisions of federal or state law or from
exercising your rights to engage in protected speech under Section 7 of the National Labor Relations Act, if applicable. Your
violation of this provision shall be a material breach of this Agreement.
Brian Cahill
March 8, 2024
Page 6
12. No
Voluntary Adverse Action. You agree that you will not voluntarily (except in response to legal
compulsion or as permitted under the Protected Rights section above) assist any person in bringing or pursuing any proposed or pending
litigation, arbitration, administrative claim, proxy contests, or other formal proceeding against any Releasee.
13. Cooperation.
You agree, both during and after the Severance Period, to cooperate fully with the Company in connection with its actual or contemplated
defense, prosecution, or investigation of any claims or demands asserted against it (and, as applicable, its current or former employees,
officers, directors or representatives) or other matters arising from events, acts, or failures to act that occurred during the period
of your employment by the Company. Such cooperation includes, without limitation, making yourself available to the Company upon reasonable
notice, without subpoena, to provide complete, truthful and accurate information in witness interviews, depositions, and trial testimony.
The Company will reimburse you for reasonable out-of-pocket expenses you incur in connection with any such cooperation (excluding foregone
wages) and will make reasonable efforts to accommodate your scheduling needs. You further agree that you will cooperate with the Company
in matters relating to corporate governance matters, Company communications and the transition of your work and responsibilities on behalf
of the Company.
In
addition, you agree that you will not, and that you will cause your affiliates, agents and representatives not to, effect or seek or participate
in, directly or indirectly, with any other person (i) any acquisition or offer, or seek to acquire, agree to acquire or acquire rights
to acquire in a manner designed to effect or obtain control of the Company, (ii) the formation or joining or participation in any
way in any group or agreement of any kind with respect to any voting securities of the Company or deposit of any voting securities of
the Company in any voting trust or subject any voting securities of the Company to any arrangement or agreement with respect to the voting
thereof, (iii) solicit or attempt to solicit or influence or encourage or participate in any solicitation of proxies or consents
to vote on any securities of the Company, (iv) nominate or seek to nominate any person to, or remove any person from, the Company’s
Board of Directors (the “Board”) or submit, initiate, make or be a proponent of, or assist, influence
or encourage, any stockholder proposal for consideration at, or bring any other business before, any stockholder meeting of the Company,
(v) seek to control or influence the management, governance, corporate structure, affairs or policies, or the Board or (vi) sell
or otherwise transfer your shares of common stock of the Company, other than in open market sale transactions where the identity of the
purchaser is not known or in underwritten widely dispersed public offerings, to any third party that, to your knowledge, would result
in such third party, together with its affiliates and associates, owning, controlling or otherwise having any beneficial or other ownership
interest in the aggregate of more than 4.99% of the shares of common stock of the Company outstanding at such time or would increase the
beneficial ownership interest of any third party who, together with its affiliates and associates, has a beneficial or other ownership
interest in the aggregate of more than 4.99% of the shares of common stock outstanding at such time. Your violation of this Section 13
shall be a material breach of this Agreement.
Brian Cahill
March 8, 2024
Page 7
14. Consulting
Opportunity. As part of this Agreement, the Company agrees to retain you as consultant for a
six (6) month period after the Separation Date (which period may be extended upon mutual agreement of the parties and may be terminated
early upon thirty (30) days’ written notice to the other party or immediately by the Company upon a Clawback Event (as defined in
Section 20)) (the “Consulting Period”). During the first three (3) months of the Consulting Period,
in exchange for your provision of consulting services (other than cooperation per Section 13) as may be requested by either the Principal
Executive Officer or Principal Financial Officer of the Company, you will be eligible to receive a monthly cash retainer of $35,000 payable
on or within thirty (30) days after the end of each applicable month, for up to a maximum of 40 hours per week. During the remaining three
(3) months of the Consulting Period, in exchange for your provision of consulting services (other than cooperation per Section 13)
as may be requested by either the Principal Executive Officer or Principal Financial Officer of the Company, you will be eligible to receive
a monthly cash retainer of $17,500 payable on or within thirty (30) days after the end of each applicable month, for up to a maximum of
20 hours per week. The Company anticipates that during the Consulting Period you will, under the direction of either the Principal Executive
Officer or Principal Financial Officer of the Company, assist with matters relating to the transition of your work and responsibilities,
excluding the financial statement close process, on behalf of the Company, including, but not limited to, the transition of any present,
prior or subsequent relationships and the orderly transfer of any such work and institutional knowledge, as directed by either the Principal
Executive Officer or Principal Financial Officer of the Company and assisting either the Principal Executive Officer or Principal Financial
Officer at the their direction. During the Consulting Period, you will not provide services on behalf of or otherwise hold yourself out
as a representative of the Company, unless specifically requested to by either the Principal Executive Officer or Principal Financial
Officer of the Company. The Company will require that you provide services from the Company’s offices (at the direction of either
the Principal Executive Officer or Principal Financial Officer of the Company) from time to time during the Consulting Period. You will
receive a Form 1099 for the cash retainer payments and will be solely responsible to pay any and all local, state, and/or federal
income, social security and unemployment taxes related to it. In the event either party terminates the Consulting Period early, any remaining
retainer payment(s) will be prorated based on the number of days worked in any applicable month.
15. No
Admissions. You understand and agree that the promises and payments in consideration of this
Agreement shall not be construed to be an admission of any liability or obligation by the Company to you or to any other person, and that
the Company makes no such admission.
16. Breach.
You agree that upon any breach of this Agreement you will forfeit all amounts paid or owing to you under this Agreement. Further, you
acknowledge that it may be impossible to assess the damages caused by your violation of the terms of Sections 9, 10, 11, 12, 13 and 14
of this Agreement and further agree that any threatened or actual violation or breach of those Sections of this Agreement will constitute
immediate and irreparable injury to the Company. You therefore agree that any such breach of this Agreement is a material breach of this
Agreement, and, in addition to any and all other damages and remedies available to the Company upon your breach of this Agreement, the
Company shall be entitled to an injunction to prevent you from violating or breaching this Agreement. In addition, in the event that either
party brings an action to enforce or effect its rights under this Agreement, the prevailing party shall be entitled to recover its costs
and expenses, including the costs of reasonable attorneys’ fees incurred in connection with such an action.
Brian Cahill
March 8, 2024
Page 8
17. Representations/Effective
Date. You hereby represent that you have: been paid all compensation owed and for all hours worked;
received all leave and leave benefits and protections for which you are eligible pursuant to the Family and Medical Leave Act, or otherwise;
and not suffered any on-the-job injury for which you have not already filed a workers’ compensation claim. You further acknowledge
and affirm that you have been advised by this writing that: (a) your waiver and release do not apply to any rights or Claims that
may arise after the execution date of this Agreement; (b) you have been advised hereby that you have the right to consult with an
attorney prior to executing this Agreement; and (c) you have been given twenty-one (21) days to consider this Agreement (although
you may choose to voluntarily execute this Agreement earlier, but not earlier than the Separation Date). This Agreement shall not be effective
until the date upon which the revocation period has expired, which shall be the eighth (8th) calendar day after you sign this Agreement
without revoking any portion of it (the “Effective Date”). You understand that if you revoke any portion of
this Agreement, the entire Agreement will be null and void, and the Company will have no obligation whatsoever to you under this Agreement.
18. Dispute
Resolution. You and the Company agree that any
and all disputes, claims, or controversies of any nature whatsoever arising from, or relating to, this Agreement or its interpretation,
enforcement, breach, performance, or execution, or any of the matters herein released (other than disputes related to the provision of
benefits where a dispute process is provided for by the applicable benefits plan document) (collectively, “Claims,”
each a “Claim”), shall be resolved, pursuant to the Federal Arbitration Act, 9 U.S.C. §1-16, and to the
fullest extent permitted by law, by final, binding, and confidential arbitration at a location closest to where you last worked for the
Company or another mutually agreeable location. The arbitration shall be conducted before a single neutral arbitrator by JAMS, Inc.
(“JAMS”) or its successor, under the then applicable JAMS Comprehensive Arbitration Rules and Procedures
(currently available at https://www.jamsadr.com/rules-comprehensive-arbitration) (“JAMS Rules”) and New Jersey
law. Both you and the Company shall opt into the Expedited Procedures under the JAMS Rules. The arbitrator shall apply substantive and
procedural New Jersey law to any dispute or Claim, without reference to any conflict-of-law provisions of any jurisdiction. To the extent
that the JAMS Rules conflict with New Jersey law, New Jersey law shall take precedence. By agreeing to this arbitration procedure,
both you and the Company waive the right to have any Claim resolved through a trial by jury or judge or an administrative proceeding.
This paragraph shall not apply to any action or Claim that cannot be subject to mandatory arbitration as a matter of law. The arbitrator
shall have sole authority for determining if a Claim is subject to arbitration, and any other procedural questions related to the dispute
and bearing on the final disposition. In addition, the arbitrator shall: (a) have the authority to compel adequate discovery for
the resolution of the dispute and to award such relief as would otherwise be available under applicable law in a court proceeding; and
(b) issue a written statement signed by the arbitrator regarding the disposition of each Claim and the relief, if any, awarded as
to each Claim, the reasons for the award, and the arbitrator’s essential findings and conclusions on which the award is based. You
and the Company shall each pay half the costs and expenses of the arbitration and each pay for its respective attorneys’ fees and
costs; provided, however, that the arbitrator shall award attorneys’ fees and costs to the prevailing party, except as prohibited
by law. To the extent JAMS does not collect or you otherwise do not pay to JAMS an equal share of all JAMS’ arbitration fees for
any reason, and the Company pays JAMS your share, you acknowledge and agree that the Company shall be entitled to recover from you half
of the JAMS’ arbitration fees invoiced to the parties (less any amounts you paid to JAMS) in a federal or state court of competent
jurisdiction. Nothing in this letter agreement is intended to prevent either you or the Company from obtaining injunctive relief in court
to prevent irreparable harm pending the conclusion of any such arbitration. Any awards or orders in such arbitrations may be entered and
enforced as judgments in the federal and state courts of any competent jurisdiction.
Brian Cahill
March 8, 2024
Page 9
19. Tax
Provisions. All payments and benefits under this Agreement will be subject to applicable withholding
for federal, state, foreign, provincial and local taxes. It is intended that all of the benefits and other payments payable under this
Agreement satisfy, to the greatest extent possible, an exemption from the application of Section 409A of the Internal Revenue Code
of 1986, as amended, including any applicable regulations and guidance thereunder (“Section 409A”) and
this Agreement will be construed to the greatest extent possible as consistent with those provisions, and to the extent not so exempt,
this Agreement will be construed in a manner that complies with Section 409A, and any ambiguities herein shall be interpreted accordingly.
Specifically, the Severance Benefits under this Agreement are intended to satisfy the exemptions from application of Section 409A
provided under Treasury Regulations Sections 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9) and each installment of Severance
Benefits, if any, is a separate “payment” for purposes of Treasury Regulations Section 1.409A-2(b)(2)(i). However, if
such exemptions are not available and you are, as of your “separation from service,” as such term is defined in Treasury Regulations
Section 1.409A-1(h) (“Separation from Service”), a “specified employee” for purposes of
Section 409A, then, solely to the extent necessary to avoid adverse personal tax consequences under Section 409A, the timing
of the Severance Benefits payments shall be delayed until the earlier of (i) six months and one day after your Separation from Service,
or (ii) your death. If Severance Benefits are not covered by one or more exemptions from the application of Section 409A and
the release could become effective in the calendar year following the calendar year in which your Separation from Service occurs, the
release will not be deemed effective, for purposes of payment of Severance Benefits, any earlier than the first day of the second calendar
year. Except to the minimum extent that payments must be delayed because you are a “specified employee” or until the effectiveness
of the release, all severance amounts will be paid as soon as practicable in accordance with this Agreement and the Company’s normal
payroll practices. For clarity, your separation constitutes an involuntary termination by the Company.
Brian Cahill
March 8, 2024
Page 10
20. Clawback
Provisions. To the extent permitted by applicable law, 100% of all Cash Severance Payments and
other benefits provided under this Agreement and all equity awards covering Company common stock that remain outstanding and/or eligible
to vest following the Separation Date will be subject to recoupment or immediate forfeiture to the Company: (1) in accordance with
applicable law or listing requirements, including pursuant to the Company’s Incentive Compensation Recoupment Policy adopted by
the Board in November 2023 and the requirements of Section 304 of the Sarbanes-Oxley Act of 2002; and/or (2) upon
either (x) a written determination in the sole discretion of the Board that you engaged in conduct that materially breached your
continuing obligations to the Company under this Agreement, and/or the Restricted Covenant Agreement, or engaged in conduct that constituted
“Cause” under the Equity Plan (either before or following the Separation Date), or (y) a finding by a court of competent
jurisdiction or an applicable Government Agency that you engaged in bad faith conduct or conduct in violation of applicable law (either
(1) or (2), a “Clawback Event”). For clarity, amounts subject to recoupment or cancellation pursuant
to a Clawback Event will be computed without regard to any taxes paid (i.e., on a gross basis without regard to tax withholdings
and other deductions) and the Board or authorized committee thereof may determine in its sole discretion, the appropriate method for recouping
or cancelling amounts, which may include, without limitation, requiring reimbursement of amounts previously paid, seeking recovery of
any proceeds realized in respect of equity awards or shares issued thereunder, cancelling or rescinding any outstanding equity-based awards
adjusting unpaid compensation or other set offs or any other method permitted by applicable law.
No recovery of compensation under any such Clawback
Event will be an event giving rise to a right to resign for good reason, constructive termination, or any similar term under any plan
of or agreement with the Company. Notwithstanding any indemnification agreement, applicable insurance policy or any other agreement or
provision of the Company’s certificate of incorporation or bylaws to the contrary, you shall not be entitled to indemnification
or advancement of expenses in connection with any enforcement of this Section 20 by the Company. The determination of whether a Clawback
Event described in (2) above has occurred, whether to recoup or forfeit and/or the extent of any such recoupment or forfeiture appropriate
and the method of such recoupment shall be determined by the Board in its sole discretion and provided further that in the event of any
litigation, pre-suit demand, government investigation or similar proceeding relating to an action or event that may constitute a Clawback
Event under 2(x) above, the Board’s determination may be deferred until such time as the Board determines to be appropriate,
in its sole discretion.
Brian Cahill
March 8, 2024
Page 11
21. Miscellaneous.
This Agreement, including its exhibits, constitutes the complete, final, and exclusive embodiment of the entire agreement between you
and the Company with regard to its subject matter, and supersedes and replaces any and all prior agreements and understandings concerning
the subject matter of this Agreement and your relationship with the Company. It is entered into without reliance on any promise or representation,
written or oral, other than those expressly contained herein, and it supersedes any other such promises, warranties, or representations.
This Agreement may not be modified or amended except in a writing signed by both you and a duly authorized officer of the Company. This
Agreement will bind the heirs, personal representatives, successors and assigns of both you and the Company, and inure to the benefit
of both you and the Company, their heirs, successors and assigns. If any provision of this Agreement is determined to be invalid or unenforceable,
in whole or in part, this determination will not affect any other provision of this Agreement and the provision in question will be modified
by the court so as to be rendered enforceable to the fullest extent permitted by law, consistent with the intent of the parties. This
Agreement will be deemed to have been entered into and will be construed and enforced in accordance with the laws of the State of New
Jersey without regard to conflict of laws principles. Any ambiguity in this Agreement shall not be construed against either party as the
drafter. Any waiver of a breach of this Agreement shall be in writing and shall not be deemed to be a waiver of any successive breach.
This Agreement may be executed in counterparts and electronic or facsimile signatures will suffice as original signatures. You acknowledge
that you have been advised that you should consult with an attorney prior to signing this Agreement (although you may choose voluntarily
not to do so).
[signatures to follow on next page]
Brian Cahill
March 8, 2024
Page 12
Sincerely, |
|
|
|
Eagle Pharmaceuticals, Inc. |
|
|
By: |
/s/ Michael Graves |
|
|
Michael Graves |
|
|
Interim Executive Chairman of the Board and |
|
|
Interim Principal Executive Officer |
|
I HAVE READ, UNDERSTAND AND AGREE FULLY TO THE
FOREGOING AGREEMENT:
/s/ Brian Cahill |
|
Brian Cahill |
|
Exhibit A: Equity Summary
Exhibit B:
Intellectual Property Assignment, Non-Disclosure, And Restrictive Covenant Agreement
Exhibit A
Equity
Awards Summary
Exhibit B
INTELLECTUAL PROPERTY ASSIGNMENT, NON-DISCLOSURE,
AND
RESTRICTIVE COVENANT AGREEMENT
Exhibit 10.2
March 8, 2024
VIA EMAIL
Steven Ratoff
Dear Steve:
This agreement contains the terms of your position
as Interim Chief Financial Officer of Eagle Pharmaceuticals, Inc. (the “Company”) with an effective date
of Mach 8, 2024 (the “Effective Date”).
As Interim Chief Financial Officer, you will report
directly to the Interim Executive Chair and will perform duties of the chief financial officer position as set forth in the Company's
bylaws and as the Board shall designate from time to time. Your role as Interim Chief Financial Officer is intended to be a temporary
position with an expected term of less than 12 months (the “Term”), though this is an at-will appointment and
may be terminated sooner or extended, by mutual agreement.
You will perform your services hereunder primarily
from the Company’s offices in New Jersey. You may be required to travel from time to time. You will be eligible for reimbursement
of reasonable, necessary expenses incurred by you in connection with the performance of your duties hereunder in accordance with the Company’s
expense reimbursement policies and procedures.
During your Term as Interim Chief Financial Officer,
you will receive compensation at the rate of $154,000 for the first three months and $77,000 per month thereafter which will be paid in
accordance with the Company’s regular payroll practices. During the Term, you will not be eligible for participation in the Company’s
executive bonus program, as the compensation set forth above is inclusive of a bonus. You will also not be eligible to participate in
the Company’s severance plans. Even if you are eligible to participate in the Company’s health and welfare plans in accordance
with the terms and eligibility criteria of such plans, you have disclosed that you do not intend to participate in the Company’s
health and welfare plans given your existing coverage through other employment or self-employment. Your employment will be subject to
the Company’s personnel policies and procedures as they may be interpreted, adopted, revised or deleted from time to time in the
Company’s sole discretion, but only to the extent that such policies and procedures are not inconsistent with the terms of this
letter.
During the Term, you will not be eligible for
compensation (either in the form of cash or equity) under the Company’s non-employee director compensation program. You have previously
been granted one or more equity awards by the Company in connection with your service as a director, which grant(s) shall continue
to vest during the Term and which shall continue to be governed in all respects by the terms of the applicable equity agreements, grant
notices, and equity plans.
The existing indemnification agreement (along
with any applicable confidentiality or non-disclosure agreement) between you and the Company will continue to govern your service as Interim
Chief Financial Officer. You represent that you are not subject to any obligation that would restrict your ability to become Interim Chief
Financial Officer of the Company and fulfill your duties to the Company in such capacity. Nothing in this offer should be construed to
interfere with or otherwise restrict in any way the rights of the Company and the Company’s stockholders to remove any individual
from the Board at any time in accordance with the Company’s certificate of incorporation, bylaws, any applicable agreements and
applicable law.
You acknowledge that as a result of your service
on the Board and as Interim Chief Financial Officer you have obtained and will obtain confidential information and proprietary information
relating to or provided by the Company and its affiliates. During and after the Term, you shall not use for your benefit or disclose confidential
information, proprietary information, knowledge or data relating to or provided by the Company and its affiliates and you agree to execute
the Company’s standard employee non-disclosure agreement upon the Company’s reasonable request.
To indicate your acceptance of the Company’s
offer, please sign and date this letter in the space provided below and return it to me. This letter sets forth the terms of your service
as Interim Chief Financial Officer and supersedes any prior representations or agreements on this subject matter, whether written or oral.
This letter will be construed and interpreted in accordance with the laws of the State of New Jersey. This letter may not be modified
or amended except by a written agreement, signed by an authorized officer of the Company and by you.
We look forward to continue working with you in your new capacity.
Sincerely, |
|
|
|
Eagle Pharmaceuticals, Inc. |
|
|
|
By: |
/s/ Michael Graves |
|
|
Name: Michael Graves |
|
|
Title: |
Interim Executive Chairman of the Board and |
|
|
|
Interim Principal Executive Officer |
|
I HAVE READ, UNDERSTAND AND AGREE FULLY TO THE
FOREGOING AGREEMENT:
/s/ Steven Ratoff |
|
Steven Ratoff |
|
v3.24.0.1
Cover
|
Mar. 08, 2024 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Mar. 08, 2024
|
Entity File Number |
001-36306
|
Entity Registrant Name |
Eagle
Pharmaceuticals, Inc.
|
Entity Central Index Key |
0000827871
|
Entity Tax Identification Number |
20-8179278
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
50
Tice Boulevard
|
Entity Address, Address Line Two |
Suite 315
|
Entity Address, City or Town |
Woodcliff Lake
|
Entity Address, State or Province |
NJ
|
Entity Address, Postal Zip Code |
07677
|
City Area Code |
201
|
Local Phone Number |
326-5300
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common
Stock, par value $0.001 per share
|
Trading Symbol |
EGRX
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Eagle Pharmaceuticals (NASDAQ:EGRX)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Eagle Pharmaceuticals (NASDAQ:EGRX)
Historical Stock Chart
Von Jun 2023 bis Jun 2024